Stock Comparison

ARVN vs LLY

Arvinas Inc vs Eli Lilly and Co

The Verdict

ARVN takes this one.

Winner

ARVN

Arvinas Inc

5.2

out of 10

Proceed with Caution

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Head-to-Head

N/A

Market Cap

$965.0B

-7.3

P/E Ratio

52.6

-19.5%

Profit Margin

N/A

-12.2%

Return on Equity

N/A

0.0

Debt-to-Equity

N/A

Aggressive

Overall Risk

Moderate

5.2

DVR Score

0.5

The Deep Dive

ARVN5.2/10

Score Change Explanation: The score has been significantly adjusted downwards from 7.7 (77/100) to 5.2 (52/100) due to several material changes and a severe lack of financial transparency in the provided real-time intelligence. The previous analysis heavily emphasized the 'significant Pfizer partnership' for the lead asset, Velexbru (ARV-471). However, recent intelligence indicates Arvinas is 'see...

Full ARVN Analysis

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.